FDA and Duke-Margolis Host Workshop on Scientific and Ethical Considerations for Including Pregnant People in Clinical Trials - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. FDA and Duke-Margolis Host Workshop on Scientific and Ethical Considerations for Including Pregnant People in Clinical Trials Part of Longer-Term Effort to Bolster Knowledge about Drug Use During Pregnancy Approximately 6 million people get pregnant every year in the United States. There are roughly 4 million live births annually. About 90% of pregnant people take a medication, including 70% who take at least one prescription medication. Medication use in pregnancy is only expected to increase, as people have babies later in life and chronic conditions like obesity and cardiovascular disease continue to grow. But there are gaps in our knowledge about how medications affect pregnancy, the pregnant person, and the fetus, partly because pregnant people are underrepresented in clinical research. We need better representation of this population in clinical studies to try to address the knowledge gaps. Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA